Neuphoria Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-369.6K | $-15.5M | $-21.4M |
| Depreciation & Amortization | $662.9K | $663.0K | $663.2K |
| Depreciation | — | $100.0K | $100.0K |
| Amortization | — | — | — |
| Stock-Based Compensation | $163.8K | $814.8K | $1.3M |
| Net Cash from Operating Activities | $77.2K | $-14.7M | $-14.6M |
| Investing Activities | |||
| Capital Expenditures | — | — | — |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | — | — | — |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $1.5M | $15.1M | $3.9M |
| Net Change in Cash | $1.6M | $505.0K | — |
| Free Cash Flow | — | — | — |